From Medscape Oncology

Coverage from the

Genitourinary Cancers Symposium (GUCS) 2023

February 16 - 18, 2023; San Francisco, CA and Virtual/Online

February 16 - 18, 2023 San Francisco, CA and Virtual/Online

GUCS 2023 Prostate Cancer Subgroup May Benefit From Intensified Therapy In a subset of patients with high-risk prostate cancer, the combination of abiraterone acetate plus prednisone (AAP) and apalutamide may improve outcomes when added to salvage radiation therapy.
Medscape Medical News, February 27, 2023
GUCS 2023 Adjuvant Nivolumab as Standard of Care in Resected Bladder Cancer Extended follow-up from the CheckMate 274 trial further supports adjuvant nivolumab as a standard of care for patients with resected muscle-invasive urothelial carcinoma.
Medscape Medical News, February 20, 2023
GUCS 2023 New Diagnostic Imaging Agent Identifies Clear Cell Renal Cancer Radiolabeled 89Zr-DFO-girentuximab PET/CT can accurately and noninvasively identify clear cell renal carcinoma, with minimal toxicity, say researchers reporting results from the phase 3 ZIRCON trial.
Medscape Medical News, February 20, 2023

Conference News

GUCS 2023 Long-Term Benefit From Nivolumab Plus Cabozantinib in RCC
Medscape Medical News, March 2, 2023
GUCS 2023 Prostate Cancer Subgroup May Benefit From Intensified Therapy
Medscape Medical News, February 27, 2023
$Pembrolizumab Activity in BCG-Refractory Papillary Bladder Cancer$ GUCS 2023 Pembrolizumab Activity in BCG-Refractory Papillary Bladder Cancer
Medscape Medical News, February 27, 2023
GUCS 2023 'Cancer' Label for Low-Risk Prostate Lesions? Patients Split
Medscape Medical News, February 21, 2023

GUCS 2023 Adjuvant Nivolumab as Standard of Care in Resected Bladder Cancer
Medscape Medical News, February 20, 2023
GUCS 2023 New Diagnostic Imaging Agent Identifies Clear Cell Renal Cancer
Medscape Medical News, February 20, 2023
GUCS 2023 Talazoparib Add-On Improves Outcomes in Metastatic Prostate Cancer
Medscape Medical News, February 17, 2023
GUCS 2023 Rucaparib Benefit in BRCA+ Prostate Cancer Confirmed
Medscape Medical News, February 17, 2023

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Popular News from GUCS 2022

PARP Inhibitors: Improving Outcomes in Metastatic Prostate Cancer Two new trials exploring this approach - olaparib in the PROpel trial and niraparib in the MAGNITUDE trial –- had slightly different results.
Medscape Medical News, Feb 22, 2022
Testicular Cancer Deaths Rising Among Hispanic Men Testicular cancer–specific mortality rates in the United States have been increasing, particularly among Hispanic men and in certain geographic locations.
Medscape Medical News, Feb 28, 2022
Bladder Cancer Need Not Always Require Radical Cystectomy Researchers involved in a large cohort study from three major institutions are calling for broader use of trimodal therapy for muscle-invasive bladder cancer.
Medscape Medical News, Mar 03, 2022

Previous Coverage